Skip to main content

Table 1 Clinicopathological features of patients with NSCLC rebiopsied after EGFR TKI resistance acquisition

From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

No. of cases123
baseline morphologyNSCLC 100%
EGFR TKI
 afatinib55
 gefitinib35
 erlotinib33
median age (range)68 (40–87)
  < 65 years (%)24
  > 65 years (%)76
sex (%)
 male53
 female70
primary EGFR mutation
 EGFR exon 19 deletion89
 EGFR exon 21 p.L858R33
 EGFR exon 19 duplication1